Sun Pharmaceutical Industries reports consolidated net loss of Rs 1276.10 crore in Q1FY14

12 Aug 2013 Evaluate

Sun Pharmaceutical Industries has reported results for the first quarter ended June 30, 2013.

On standalone basis, the company has posted a fall of 84.38% in its net profit at Rs 45.70 crore for the quarter ended June 30, 2013 as compared to Rs 292.63 crore for the same quarter in the previous year. The total income of the company has decreased by 40.84% to Rs 582.54 crore for quarter under review as compared to Rs 984.65 crore for the quarter ended June 30, 2012.

Other Operating Income for the Quarter ended June 30, 2012 and Year ended March 31, 2013 mainly represents Income from Partnership Firms. With effect from August 31, 2012 these Partnership Firms have been converted under Part IX of the Companies Act, 1956 into Private Limited companies, being wholly owned subsidiaries of the Company and accordingly, the corresponding figures for other quarters are not comparable.

On the consolidated basis, the Company reported net Loss after taxes and minority interest at Rs 1276.10 crore for the quarter against net profit after taxes and minority interest of Rs 795.55 crore for the June quarter of the previous year.  However, the Company’s total income grew by 34.68% at Rs 3577.56 crore for the quarter under review as against Rs 2656.25 crore for the corresponding quarter of the previous year.

The Scheme of Arrangement in the nature of spin off and transfer of Domestic Formulation undertaking of the Company to Sun Pharma Laboratories wholly owned subsidiary, from the close of the business hours on March 31, 2012, being the appointed date, was approved by High Courts of Gujarat and Bombay vide their Orders dated May 03, 2013 and the said Scheme became effective from May 27, 2013 upon filing of the said Orders with the Registrar of Companies. Accordingly, the effect of the Scheme was given in the standalone financial results for the year ended March 31, 2013 only on an annual basis and approved by the Board of Directors at their meeting held on May 28, 2013. However, the standalone financial results for quarterly periods during the year ended March 31, 2013 had been so approved without giving effect to the said Scheme end have not been restated in the above Key information on the standalone financial results. In view of this, the figures for the quarter ended June 30, 2013 are not comparable with the figures for the quarter ended March 31, 2013 and June 30, 2012 due to effect of spin off and transfer of Domestic Formulation undertaking of the Company

Sun Pharma Inds. Share Price

1796.25 -8.70 (-0.48%)
08-Dec-2025 09:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1796.25
Dr. Reddys Lab 1274.40
Cipla 1512.50
Zydus Lifesciences 934.40
Lupin 2094.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×